Pre-made Sarilumab benchmark antibody ( Whole mAb, anti-IL6R therapeutic antibody, Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-507

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-507 Category Tag

Product Details

Pre-Made Sarilumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.

Products Name (INN Index)

Pre-Made Sarilumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody

INN Name

Sarilumab

Target

IL6R

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2011

Companies

Asahi Kasei Pharma Corp,Regeneron Pharmaceuticals,Sanofi

Conditions Approved

Rheumatoid arthritis

Conditions Active

Juvenile rheumatoid arthritis

Conditions Discontinued

Ankylosing spondylitis,COVID-19,Giant cell arteritis,Polymyalgia rheumatica,Uveitis

Development Tech

VelocImmune Mouse

Previous Name

NA

Gm Offical Target Name

IL6R

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide